Print PDF

2024 Antitrust in Healthcare

New Competition Theories in Life Sciences Mergers
The Ritz-Carlton, Pentagon City
06.05.2024 | 11:15 AM - 12:15 PM

Recently, US merger enforcement agencies have challenged life sciences mergers using novel theories of harm. These include competition foreclosure by rebate bundling and acquisitions that stifle innovation. This panel will discuss these novel theories, their relevance in recent cases (e.g., Amgen/Horizon merger), and economic considerations and analyses to evaluate them.


  • James Lee, Cornerstone Research, Los Angeles, CA


  • John D. Carroll, Sheppard Mullin Richter & Hampton LLP, Washington, DC
  • Renata B. Hesse, Sullivan & Cromwell LLP, Washington, DC
  • Stephen Mohr, Assistant Director, Merger I, Federal Trade Commission, Washington, DC

Click here to register.


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.